SCHEMBL1409155

SCHEMBL1409155

[CH2]C(C)C#CCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37827 0.75
SCHEMBL645473 0.73
SCHEMBL1491982 0.73
SCHEMBL2121156 0.73
SCHEMBL27858218 0.73
SCHEMBL130181 0.73
SCHEMBL8960466 0.73
SCHEMBL8960438 0.73
SCHEMBL2161000 0.71
SCHEMBL8960280 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917239-A1 FLUOROPROSTAGLANDINS NITRODERIVATIVES Pfizer, Inc. (US) 2008-05-07 EP claimed
WO-2007000642-A1 FLUOROPROSTAGLANDINS NITRODERIVATIVES PFIZER INC. (US) 2007-01-04 WO claimed
EP-0171992-B1 PHARMACEUTICALS CONTAINING PROSTAGLANDIN I2 MITSUBISHI KASEI CORPORATION (JP) 1990-06-06 EP claimed
US-4837342-A STABILITY SAGAMI CHEMICAL RESEARCH CENTER (JP) 1989-06-06 US claimed
US-4699921-A CIRCULATION AMELIORATING AND ANTIULCER EFFECT MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1987-10-13 US claimed
EP-0234576-A1 Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient SAGAMI CHEMICAL RESEARCH CENTER (JP) 1987-09-02 EP claimed
EP-0171992-A2 Pharmaceuticals containing prostaglandin I2 MITSUBISHI KASEI CORPORATION (JP) 1986-02-19 EP claimed
CN-116143757-B Multifunctional compound, composition and application of degradable BTK kinase 杭州和正医药有限公司 2024-07-05 CN disclosed
CN-118302418-A Aromatic heterocyclic compound and application thereof 中国科学院上海药物研究所 2024-07-05 CN disclosed
EP-4393907-A1 POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION Neushen Therapeutics (Shanghai) Co., Ltd (CN) 2024-07-03 EP disclosed
CN-118103775-A Composition for forming resist underlayer film 日产化学株式会社 2024-05-28 CN disclosed
EP-4365178-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF Shanghai Allist Pharmaceuticals Co., Ltd. (CN) 2024-05-08 EP disclosed
CN-117832494-A Battery cell 珠海冠宇电池股份有限公司 2024-04-05 CN disclosed
US-4699921-A CIRCULATION AMELIORATING AND ANTIULCER EFFECT MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1987-10-13 US disclosed
US-4699921-A CIRCULATION AMELIORATING AND ANTIULCER EFFECT MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) 1987-10-13 US disclosed
EP-0236510-A1 PROSTACYCLINS AND DRUGS CONTAINING THE SAME MITSUBISHI KASEI CORPORATION (JP) 1987-09-16 EP disclosed
EP-0234576-A1 Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient SAGAMI CHEMICAL RESEARCH CENTER (JP) 1987-09-02 EP disclosed
EP-0234158-A1 (2-Chloro-3-oxo-1-alkenyl)bicyclo (3.3.0.) octene derivative and process for preparing the same MITSUBISHI KASEI CORPORATION (JP) 1987-09-02 EP disclosed
EP-0171992-A2 Pharmaceuticals containing prostaglandin I2 MITSUBISHI KASEI CORPORATION (JP) 1986-02-19 EP disclosed
EP-0171992-A2 Pharmaceuticals containing prostaglandin I2 MITSUBISHI KASEI CORPORATION (JP) 1986-02-19 EP disclosed